Acadia wins first FDA approval for Rett syndrome drug

The FDA on Friday approved Acadia Pharmaceuticals’ treatment for Rett syndrome, a rare neurodevelopmental disorder, which will be sold under the brand name Daybue (trofinetide), the company announced.